Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Glomerulonephritis Market Growth in 2025?
The market for glomerulonephritis has seen substantial growth in recent years. The market, valued at $11.06 billion in 2024, is projected to increase to $11.64 billion in 2025, with a compound annual growth rate (CAGR) of 5.3%. Factors that have contributed to this historical growth include a surge in kidney-related disorders, the occurrence of infections like post-streptococcal glomerulonephritis, advancement in research and development activities, an increased number of kidney failure cases, and heightened awareness about kidney diseases.
What Is the Forecast for the Glomerulonephritis Market Size Through 2029?
Anticipations are high for substantial expansion in the glomerulonephritis market in the approaching years. The market is projected to escalate to $14.14 billion in 2029, experiencing a compound annual growth rate (CAGR) of 5.0%. This projected growth span can be credited to factors such as the escalating occurrence of diabetes, an augmenting elderly demographic, enhanced investments in healthcare expenditure, a swell in dialysis patients, and an upsurge in autoimmune diseases. Key trends to watch out for during this forecast period encapsulate the introduction of innovative treatments and therapies, progression in diagnostic technologies, breakthrough therapeutics and therapies, inter-company collaborations, and the use of intravenous immunoglobulin therapy.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21193&type=smp
What are the Key Market Players in Glomerulonephritis Market and How They’re Evolving?
Major companies operating in the glomerulonephritis market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Asahi Kasei Medical Co. Ltd., Boehringer Ingelheim International GmbH, DaVita Inc., Biogen Inc., Merit Medical Systems Inc., Apellis Pharmaceuticals Inc., MorphoSys AG, Travere Therapeutics Inc., Vera Therapeutics Inc., Calliditas Therapeutics AB, Omeros Corporation, Otsuka Pharmaceutical Co. Ltd., Aurinia Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., NovelMed Therapeutics Inc.
What Are the Primary Growth Drivers in the Glomerulonephritis Market?
Anticipated growth in the glomerulonephritis market is largely due to the increasing incidence of kidney disorders. Broadly speaking, these disorders impact the kidney’s structure or functioning, causing issues with waste filtration, removal, and fluid equilibrium. The uptick in kidney disorders can be traced back to an aging population, an increase in chronic conditions like diabetes and hypertension, and certain lifestyle factors. Kidney dysfunctions can originate from immune system abnormalities, chronic inflammation, or structural damage, all of which can disrupt kidney filtration and operations. For example, figures released by the Australian Institute of Health and Welfare, a government body in Australia, in December 2024, indicate that the death rate due to chronic kidney disease (CKD) increased by 4.2% in 2021 and 6.2% in 2022. Additionally, roughly 2 million hospitalizations in 2021-2022 were attributed to CKD, making up 18% of all hospitalizations in Australia. As a result of these factors, the increasing occurrence of kidney disorders is predicted to be a significant driver for the expansion of the glomerulonephritis market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21193&type=smp
What Are the Leading Segments in the Global Glomerulonephritis Industry?
The glomerulonephritis market covered in this report is segmented –
1) By Type: Acute Glomerulonephritis, Chronic Glomerulonephritis
2) By Diagnosis: Urine And Blood Tests, Imaging Tests, Kidney Biopsy, Other Diagnosis
3) By Treatment: Medication, Surgery, Dialysis, Other Treatments
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
5) By End-User: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Acute Glomerulonephritis: Post-infectious Glomerulonephritis, IgA Nephropathy, Lupus Nephritis, Rapidly Progressive Glomerulonephritis (RPGN), Goodpasture Syndrome
2) By Chronic Glomerulonephritis: Focal Segmental Glomerulosclerosis (FSGS), Membranous Nephropathy, Minimal Change Disease, Alport Syndrome, Diabetic Nephropathy, Hypertensive Nephrosclerosis
What Are the Key Market Trends in the Glomerulonephritis Industry?
Leading businesses in the glomerulonephritis market are targeting non-immunosuppressive solutions as a means of meeting healthcare demands and enhancing patient health results. Non-immunosuppressive solutions aim to address health issues without compromising the immune system’s functionality. For example, in September 2024, a US biopharmaceutical firm, Travere Therapeutics Inc., launched FILSPARI (sparsentan), a non-immunosuppressive drug approved by the FDA for addressing IgA nephropathy, a kidney disorder. This medication is the singular non-immunosuppressive solution proven to effectively decelerate the kidney’s functional deterioration in sufferers. The approval of FILSPARI represents a significant advance in treating IgA nephropathy, the prevalent type of primary glomerulonephritis and provides a novel alternative for patients earlier faced with limited options. This approval emphasizes Travere’s determination to better patient results within kidney disease context.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/glomerulonephritis-global-market-report
What Is the Regional Outlook for the Glomerulonephritis Market?
North America was the largest region in the glomerulonephritis market in 2024. The regions covered in the glomerulonephritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21193
This Report Delivers Insight On:
1. How big is the glomerulonephritis market, and how is it changing globally?
2. Who are the major companies in the glomerulonephritis market, and how are they performing?
3. What are the key opportunities and risks in the glomerulonephritis market right now?
4. Which products or customer segments are growing the most in the glomerulonephritis market?
5. What factors are helping or slowing down the growth of the glomerulonephritis market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model